Process for production, recovery and purification of capsular polysaccharide polyribosyl-ribitol-phosphoric acid (PRP) and uses thereof

A technology of capsular polysaccharides and ribitol, applied in the field of polysaccharide purification, can solve the problems of not using tangential microfiltration

Pending Publication Date: 2022-08-05
INSTITUTO BUTANTAN
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Furthermore, in this document there is no unit operation using tangential microfiltration as disclosed by the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for production, recovery and purification of capsular polysaccharide polyribosyl-ribitol-phosphoric acid (PRP) and uses thereof
  • Process for production, recovery and purification of capsular polysaccharide polyribosyl-ribitol-phosphoric acid (PRP) and uses thereof
  • Process for production, recovery and purification of capsular polysaccharide polyribosyl-ribitol-phosphoric acid (PRP) and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0065] While the present invention may be susceptible to different forms, preferred embodiments are shown in the accompanying drawings and the following detailed discussion, it being understood that the present embodiments are to be considered illustrative of the principles of the invention and are not intended to The invention is limited to what has been shown and described herein.

[0066] The present invention relates to a method for the production and purification of the capsular polysaccharide polyribosyl-ribitol-phosphate (PRP) produced by the bacterium Haemophilus influenzae type b (Hib). More specifically, the present invention relates to a method for the production and purification of polysaccharides (PRPs) having a purity and molecular mass suitable for subsequent chemical conjugation and production of Hib conjugate vaccines.

[0067] figure 1 The chemical structure of the polysaccharide capsule (PRP) of Haemophilus influenzae type b is shown.

[0068] 1. Cultur...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to methods comprising the production and purification of capsular polysaccharide polyribosylribitol phosphate (PRP) produced by the bacterium Haemophilus influenzae type b (Hib) to obtain polysaccharides of suitable molecular mass and purity for the subsequent formulation of Hib conjugate vaccines. The invention also relates to an application of the capsular polysaccharide polyribosyl ribitol phosphate (PRP) in preparation of vaccines.

Description

[0001] Field of Invention [0002] The present invention relates to a method for the production and purification of the capsular polysaccharide polyribosyl-ribitol-phosphate (PRP) produced by the bacterium Haemophilus influenzae type b (Hib). More specifically, the present invention relates to a method of purification of polysaccharides (PRPs) having a purity and molecular weight suitable for subsequent formulation of Hib conjugate vaccines. [0003] Background of the Invention [0004] Haemophilus influenzae is a gram-negative, aerobic / microaerophilic bacterium with a cocobacillary morphology that is immotile and non-spore-forming, present in 75% of healthy children and adults of the nasopharynx and thus constitute asymptomatic carriers. There are no records of this microorganism being detected in any other animal species (ADA and ISAACS, 2003; KELLY et al., 2004). [0005] It was isolated by Pfeiffer during the influenza pandemic in 1890 and was mistaken for the cause of t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12P19/04C12N1/20C12R1/21A61K39/102
CPCC12P19/04A61K39/102C12N1/20C12R2001/21C12N1/205
Inventor M·塔卡其J·卡布雷拉-克雷斯波R·G·西马斯L·G·布拉加S·M·F·阿尔巴尼
Owner INSTITUTO BUTANTAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap